What is Transgene Biotek share price return in the past 10 years?

Transgene Biotek Ltd share price has appreciated 5.6% annually (CAGR) over the past ten years.

Transgene Biotek Ltd - Stock Valuation and Financial Performance

Name: Transgene Biotek
Brand: Transgene Biotek

BSE: 526139 | NSE: | Hospital & Healthcare Services | Small Cap

Place order

Transgene Biotek Share Price

₹6.50 -0.23 -3.42%
as on 21-Nov'24 16:59

DeciZen - make an informed investing decision on Transgene Biotek

Based on:

Data

M-Cap below 100cr DeciZen not available

Transgene Biotek stock performance -

PE Chart Key Ratios

P/E Ratio (SA):

0.00

Market Cap:

49.3 Cr.

52-wk low:

5.8

52-wk high:

12.5

Is Transgene Biotek Ltd an attractive stock to invest in?

1. Is Transgene Biotek Ltd a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Transgene Biotek Ltd is a below average quality company.

2. Is Transgene Biotek Ltd undervalued or overvalued?

The key valuation ratios of Transgene Biotek Ltd's currently when compared to its past seem to suggest it is in the Undervalued zone.

3. Is Transgene Biotek Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Transgene Biotek Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Transgene Biotek:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	TTM
ROCE % ⓘ	-48.1%	-9.3%	-11.9%	-17.1%	-9.1%	-21.4%	-34.9%	-49.1%	-73.2%	-57.5%	-
Value Creation Index ⓘ	-4.4	-1.7	-1.9	-2.2	-1.7	-2.5	-3.5	-4.5	NA	NA	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	1	0.3	0.2	0.3	0.1	0.1	0	0.2	0.1	0.1	0
Sales YoY Gr.	-	-68.4%	-41.9%	55.6%	-57.1%	-41.7%	-100%	NA	-47.1%	-33.3%	-
Adj EPS ⓘ	-7	-2.5	-2.8	-2.6	-1.1	-1.3	-1.5	-1.4	-1.4	-0.8	-0
YoY Gr.	-	NA	NA	NA	NA	NA	NA	NA	NA	NA	-
BVPS (₹) ⓘ	26	23.5	20.4	5.5	4.6	3.4	2	0.6	-0	-0.8	-0.9
Adj Net Profit ⓘ	-52.8	-19	-21.5	-19.9	-8.5	-10	-11	-10.4	-10.4	-6	0
Cash Flow from Ops. ⓘ	-2.1	-1	0	0	-0.6	-1.7	0.1	0	0.1	0	-
Debt/CF from Ops. ⓘ	-6.2	-15.2	818	692.9	-15.8	-5.3	74.1	901.5	122.9	43733	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	-26.7%	-12.9%	NA	-33.3%
Adj EPS ⓘ	NA	NA	NA	NA
BVPSⓘ	-168.1%	-170.8%	-174.4%	NA
Share Price	5.6%	20.7%	20.7%	-21.6%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	TTM
Return on Equity % ⓘ	-20.3	-10.1	-12.9	-20.3	-22.2	-33	-53.3	-105.6	-465.8	187.6	3.5
Op. Profit Mgn % ⓘ	-185.4	-480.9	-623.1	-910.9	-1779.2	-944.2	-24147.1	-307.2	-531.8	-1104.2	-439.1
Net Profit Mgn % ⓘ	-5376.3	-6047.7	-11864.4	-7071.7	-7161.3	-14076	-306601.7	-6153.4	-11998.4	-10901.5	-113.7
Debt to Equity ⓘ	0.1	0.1	0.1	0.4	0.3	0.4	0.7	2.4	-61	-2.1	-
Working Cap Days ⓘ	28,752	87,392	1,34,729	54,937	75,086	1,21,127	24,16,578	51,163	1,00,234	1,58,615	893
Cash Conv. Cycle ⓘ	6,555	19,843	18,102	1,132	155	172	3,537	52	234	411	-8,834

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 3.50%

Sales growth has been subdued in last 3 years 0.00%

Sales growth is not so good in last 4 quarters at 0.00%

Latest Financials - Transgene Biotek Ltd.

	Standalone	Consolidated
TTM EPS (₹)	-0	-0
TTM Sales (₹ Cr.)	0.2	0.2
BVPS (₹.) ⓘ	-0.9	1.4
Reserves (₹ Cr.) ⓘ	-83	-65
P/BV ⓘ	-7.33	4.52
PE ⓘ	0.00	0.00

From the Market
52 Week Low / High (₹)	5.79 / 12.46
All Time Low / High (₹)	0.10 / 322.50
Market Cap (₹ Cr.)	49.3
Equity (₹ Cr.)	75.8
Face Value (₹)	10
Industry PE ⓘ	40.5

Management X-Ray of Transgene Biotek:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Transgene Biotek

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Transgene Biotek

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Sales	0.31	0.18	0.28	0.12	0.07	0	0.17	0.09	0.06	0.23
Operating Expenses ⓘ	1.83	1.31	2.84	2.22	0.74	0.87	0.69	0.55	0.66	0.84
Manufacturing Costs	0.34	0.15	0.13	0.07	0.10	0.20	0.02	0.01	0.02	0
Material Costs	0.01	0	0	0.05	0.03	0.01	0.06	-0.05	0.07	0
Employee Cost	0.75	0.39	0.27	0.20	0.25	0.29	0.25	0.29	0.30	0.31
Other Costs ⓘ	0.72	0.78	2.44	1.90	0.37	0.36	0.37	0.29	0.27	0.53
Operating Profit ⓘ	-1.51	-1.13	-2.56	-2.10	-0.67	-0.86	-0.52	-0.46	-0.61	-0.61
Operating Profit Margin (%)	-480.0%	-623.0%	-910.0%	-1,779.3%	-944.0%	-24,147.1%	-307.0%	-531.0%	-1,104.2%	-258.0%
Other Income ⓘ	0.02	0.17	0.66	7.37	2.04	0.18	0.27	0.21	0.18	0.18
Interest ⓘ	0.36	0.07	0.43	1.03	0.26	0.38	0.27	0.23	0.62	0.14
Depreciation ⓘ	17.18	20.50	17.53	9.89	9.89	9.90	9.91	9.92	4.95	0.09
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Profit Before Tax ⓘ	-19.04	-21.54	-19.86	-5.65	-8.79	-10.96	-10.43	-10.40	-6.01	-0.66
Tax ⓘ	0	0	0	0.79	0	0	0	0	0	0
Profit After Tax	-19.04	-21.54	-19.86	-6.44	-8.79	-10.96	-10.43	-10.40	-6.01	-0.66
PAT Margin (%)	-6,047.6%	-11,864.4%	-7,071.7%	-5,445.3%	-12,334.2%	-3,06,601.7%	-6,153.4%	-11,998.4%	-10,901.5%	-279.0%
Adjusted EPS (₹)	-2.5	-2.8	-2.6	-0.9	-1.2	-1.5	-1.4	-1.4	-0.8	-0.1
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	178.15	154.66	41.29	34.85	26.06	15.10	4.66	-0.20	-6.21	-6.87
Share Capital ⓘ	75.77	75.77	75.77	75.77	75.77	75.77	75.77	75.77	75.77	75.77
Reserves ⓘ	102.38	78.89	-34.48	-40.92	-49.71	-60.67	-71.11	-75.97	-81.98	-82.64
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	14.34	15.28	14.76	9.85	9.13	10.33	11.33	12.02	13.12	14
Long Term Debt	6.27	6.34	5.19	3.84	4.10	4.28	4.54	4.77	4.95	5.08
Short Term Debt	8.07	8.94	9.57	6	5.04	6.05	6.79	7.25	8.17	8.92
Trade Payables	15.60	0.84	0.54	0.55	0.29	0.38	0.24	0.20	0.23	0.20
Others Liabilities ⓘ	122.23	122.30	31.58	31.41	31.18	31.06	30.76	25.20	25.33	25.11
Total Liabilities ⓘ	330.33	293.09	88.18	76.66	66.66	56.86	46.99	37.22	32.48	32.44
Fixed Assets
Gross Block	208.37	206.42	107.86	107.55	107.58	107.58	107.61	107.61	107.61	107.61
Accumulated Depreciation	44.97	65.47	46.69	56.58	66.48	76.38	86.28	96.21	101.16	101.25
Net Fixed Assetsⓘ	163.40	140.95	61.16	50.97	41.10	31.20	21.32	11.40	6.45	6.36
CWIP ⓘ	0.29	0.29	2.04	1.87	1.87	1.87	1.87	1.87	1.87	1.87
Investmentsⓘ	92.20	92.20	0	0	0	0	0.01	0.11	0.11	0.10
Inventories	0.07	0.07	0.07	0.04	0.03	0.04	0.02	0.09	0.03	0.03
Trade Receivables	16.39	1.63	0.01	0	0	0	0	0	0	0
Cash Equivalents	0.03	0.03	0.05	0.10	0.10	0.04	0.01	0.02	0	0.01
Others Assetsⓘ	57.95	57.92	24.85	23.68	23.56	23.71	23.76	23.74	24.02	24.08
Total Assets ⓘ	330.33	293.09	88.18	76.66	66.66	56.86	46.99	37.22	32.48	32.44

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	-0.95	0.02	0.02	-0.63	-1.74	0.14	0.01	0.10	0	0
PBT ⓘ	-19.04	-21.54	-19.86	-6.44	-8.79	-10.96	-10.43	-10.40	-6.01	-0.66
Adjustment ⓘ	17.54	20.58	19.24	5.06	8.20	10.10	10	9.98	4.96	0.05
Changes in Working Capital ⓘ	0.55	0.98	0.65	0.75	-1.14	1	0.45	0.52	1.05	0.61
Tax Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Cash Flow From Investing Activity ⓘ	-0.02	-0.02	0	3.05	1.74	0	-0.04	-0.10	-0.01	0
Capex	0	0	0	3.37	1.74	0	-0.03	0	0	0
Net Investments	0	0	0	0	0	0	0	0	0	0
Others ⓘ	-0.02	-0.02	0	-0.32	0	0	-0.01	-0.10	-0.01	0
Cash Flow From Financing Activityⓘ	0.94	0	0	-2.37	0	-0.20	0	0	0	0
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	0	0	0	0	0	0	0	0	0	0
Interest Paid ⓘ	0	0	0	-0.75	0	0	0	0	0	0
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	0.95	0	0	-1.62	0	-0.20	0	0	0	0
Net Cash Flow ⓘ	-0.02	0	0.02	0.05	0	-0.06	-0.02	0	-0.01	0

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	-10.14	-12.94	-20.27	-16.91	-28.87	-53.27	-105.59	N/A	N/A	N/A
ROCE (%)	-9.27	-11.85	-17.1	-9.06	-21.35	-34.91	-49.07	N/A	N/A	N/A
Asset Turnover Ratio	0	0	0	0	0	0	0	0	0	0.01
PAT to CFO Conversion(x)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Working Capital Days
Receivable Days	0	0	1,060	0	0	0	0	0	0	0
Inventory Days	80	132	85	166	187	3,549	63	242	425	53
Payable Days	0	0	0	4,079	4,527	8,270	1,858	-1,747	1,188	0

Transgene Biotek Ltd Stock News

Transgene Biotek Ltd FAQs

What is the share price of Transgene Biotek?

Company share prices are keep on changing according to the market conditions. The closing price of Transgene Biotek on 21-Nov-2024 16:59 is ₹6.50.

What is the market cap of Transgene Biotek?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 21-Nov-2024 16:59 the market cap of Transgene Biotek stood at ₹49.33.

What is the P/E ratio of Transgene Biotek?

The latest P/E ratio of Transgene Biotek as of 21-Nov-2024 16:59 is 0.00.

What is the P/B ratio of Transgene Biotek?

The latest P/B ratio of Transgene Biotek as of 21-Nov-2024 16:59 is -7.33.

What is the 52-week high and low of Transgene Biotek?

The 52-week high of Transgene Biotek is ₹12.46 and the 52-week low is ₹5.79.

What is the TTM revenue of Transgene Biotek?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Transgene Biotek is ₹0.20 ( Cr.) .

About Transgene Biotek Ltd

Transgene Biotek Ltd (TBL) was set up in 1991, and was probably the first true Biotechnology Company in India. It is listed on the Indian Stock Exchanges and is involved in the development of several cutting edge technologies.

From the knowledge gained in developing recombinant vaccines successfully since 1994, and having gained considerable experience in improving the technology processes of those products, Transgene has expanded its product portfolio to other therapeutic areas such as Bio-generics, Oncology and New Drug Delivery Systems among others.

In line with its expanded product development portfolio, Transgene is modifying its existing infrastructure to cater to further Research & Development activities and is presently constructing a new manufacturing facility to meet WHO and US FDA standards. Transgene is focused on maximizing synergies through strategic partnerships. We are excited to explore opportunities with partners and catalyze technological advances in the field of biotechnology. Since 1994, Transgene Biotek has developed or has been involved in the development of technology for several different bio-pharmaceuticals, recombinant vaccines and therapeutics. We have extensive experience and expertise to assist you in recombinant drug development, characterization, testing and validation.

Product range of the company includes:

The company is engaged in manufacturing drugs for:

New Drug Delivery System (NDDS)